Navigation Links
Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch
Date:9/3/2008

1,000 women of reproductive age highlight that more than 30 percent of women are not satisfied with their current contraceptive methods. In addition, the vast majority of these women found Agile's low-dose contraceptive patch appealing and over 50 percent would talk with their doctors about using it. Agile's low-dose contraceptive patch is expected to fill a sizeable need in the $6 billion global ($2.5 billion U.S.) hormonal contraceptive market.

About Estrogen

Estrogen is associated with certain common side effects, such as breast tenderness, bloating/weight gain and nausea. These side effects are believed to be related to the level of hormones delivered into the blood stream, particularly with higher levels of estrogen. In some rare cases, high estrogen levels are thought to be linked with serious, cardiovascular side effects in some women. Therefore, low doses of estrogen in hormonal contraception are desired.

According to FDA labeling, women using Ortho EVRA(R) are exposed to about 60 percent more estrogen than if they were using typical birth control pills. Increased levels of estrogen may increase the risk of blood clots, which lead the FDA to add precautions to Ortho EVRA's label.

About Agile Therapeutics, Inc.

Agile Therapeutics is a privately held, specialty pharmaceutical company focused on the development of innovative women's healthcare products. Historically, the women's healthcare market offers unique opportunities to a company with proven expertise in clinical development, regulatory affairs, transdermal drug delivery and commercialization experience.

Agile's current venture investors include TL Ventures, Novitas Capital (formerly PA Early Stage Partners), ProQuest Investments, and The Hillman Company. The Company has raised a total of $35 million in venture funding to date. For more information, please visit http://www.agiletherapeutics.com.


'/>"/>

SOURCE Agile Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Tobira Therapeutics Inc. Receives US Patent for TBR-652
2. MabVax Therapeutics Closes Two Licensing Agreements With Sloan-Kettering Institute for Cancer Research
3. Cell Therapeutics Announces that the European Organization for Research and Treatment of Cancer Completes Enrollment in Phase II Clinical Trial of Brostallicin as First Line Therapy for Advanced or Metastatic Soft Tissue Sarcoma
4. Amicus Therapeutics Announces Second Quarter 2008 Financial Results
5. Cara Therapeutics Announces Successful Completion of Phase I Clinical Trial of Novel Analgesic, CR845
6. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
7. Nile Therapeutics Announces Dosing in Second Phase Ib Study of CD-NP in Heart Failure Patients
8. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
9. Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
10. Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters
11. Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinsons Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Sept. 19, 2014  The board of directors of ... quarterly cash dividend of $0.42 per share.  ... to stockholders of record at the close of business ... is a global, research-based biopharmaceutical company formed in 2013 ... use its expertise, dedicated people and unique approach to ...
(Date:9/19/2014)... 19, 2014 Merck (NYSE: MRK ), known ... Canada , is teaming with celebrity chef and ... Tus Metas , an educational program encouraging Hispanics with type 2 ... key treatment goal to help reduce the risk of serious health ... at a higher risk for developing type 2 diabetes than non-Hispanic ...
(Date:9/19/2014)... , Sept. 19, 2014 Larry J. ... CVS ), will speak before the National Press Club ... discuss the company,s recent move to stop selling tobacco products ... the future of health. "Dramatic changes in our ... care providers and government," Merlo has said. "CVS Health has ...
Breaking Medicine Technology:Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 2Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 3Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 4Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 5CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 2CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 3
... 23 DuPont (NYSE: DD ) and ... joint venture to develop, manufacture and commercialize advanced surgical ... venture will be named Actamax Surgical Materials LLC. Under ... share a 50 percent interest. The joint venture ...
... Precision Therapeutics announced today that President and Chief ... Magazine 2010 Pacesetters Award.  The award honors thirteen ... influence in the community-at-large as well as within ... Tuesday, September 21st at the Kean Theatre in ...
Cached Medicine Technology:DuPont and DSM Announce Joint Venture in Surgical Biomedical Materials 2DuPont and DSM Announce Joint Venture in Surgical Biomedical Materials 3DuPont and DSM Announce Joint Venture in Surgical Biomedical Materials 4Precision Therapeutics President and CEO Sean McDonald Recognized as a Leading Business Executive and Recipient of 2010 Pacesetters Award 2
(Date:9/19/2014)... -- As kids transition from elementary to middle school, ... a recent study. But the researchers studying ... verbal and physical bullying declines as students get older. ... strategies must address all types of bullying as well ... researchers said. The study was published recently in ...
(Date:9/19/2014)... 9/18/14) A leading Dartmouth researcher, working with The Melanoma ... paper published today in the Journal of the ... the risk of melanoma. , "For the first time, ... of these telomeres play a part in the risk ... Mark Iles, PhD, School of Medicine at the University ...
(Date:9/19/2014)... FRIDAY, Sept. 19, 2014 (HealthDay News) -- U.S. military ... risk of skin cancer, according to a new study. ... serving abroad, researchers revealed. In some cases, military personnel ... in the color, shape or size of their moles ... can be risk factors for skin cancer, the study ...
(Date:9/19/2014)... FRIDAY, Sept. 19, 2014 (HealthDay News) -- The U.S. Food ... Trulicity, on Thursday. Trulicity is part of a class of ... adults with type 2 diabetes. "Trulicity is a ... to existing treatment regimens to control blood sugar levels in ... deputy director of the FDA,s Office of Drug Evaluation II, ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 MetroMD, a leading ... the “God Particle” of human health. This therapy has grown ... making the therapy more effective, safe and dependable. It has ... them an opportunity to live a very healthy and active ... concept of HGH therapy, a senior therapist at MetroMD said, ...
Breaking Medicine News(10 mins):Health News: Cyberbullying Seems to Ramp Up in Middle School 2Health News:Melanoma risk found to have genetic determinant 2Health News:Some U.S. Troops May Face Greater Skin Cancer Risk 2Health News:FDA Approves Another Weekly Injectable Drug for Type 2 Diabetes 2Health News:MetroMD Announces Better HGH Therapy - the ‘God Particle’ of Human Health 2
... 6 Cowen Group, Inc. (Nasdaq: COWN ) ... a Senior Analyst covering managed care and health care service ... covered health care services stocks from 1999 to 2008. ... the lead analyst covering healthcare services. Between 2000 and ...
... 6 Prism Pharmaceuticals, Inc.,announced today that Dr. Warren ... the 27th Annual J.P. Morgan Healthcare Conference on,Tuesday, January ... a.m. (Eastern,Time). The conference will be held at ... Dr. Cooper will present corporate ...
... SMTS ) will release its financial results for ... before the opening of the market on,Wednesday, January 21, ... will host a conference call that will be webcast ... On the conference call, Bruce Barrett, ...
... at Home Depot saw big increase in employees working out ... to work out works, a new study says. , ... to support workers in setting exercise goals notably increased their ... The findings were published in the February edition of ...
... Design Creates Tangible Value by Revealing New Revenue ... LLC, a firm that specializes in designing customer-centric ... for growth-oriented companies, today announced its official launch. ... build and launch new services around business opportunities ...
... Population is Undertreated When Compared to California, According ... Mass., Jan. 6 Decision Resources, one of ... on pharmaceutical and healthcare issues, finds that Florida ... the Alzheimer,s disease drug market despite the large ...
Cached Medicine News:Health News:Cowen Adds Health Care Service Analyst to Equity Research Department 2Health News:Somanetics Corporation to Release Fourth Quarter and Fiscal 2008 Financial Results and Host Conference Call January 21, 2009 2Health News:Employer-Sponsored Workouts Boost Workers' Health 2Health News:First Service Design Firm Launches in United States 2Health News:Florida and California Represent Equivalent Areas of Opportunity in the Alzheimer's Disease Drug Market 2Health News:Florida and California Represent Equivalent Areas of Opportunity in the Alzheimer's Disease Drug Market 3
Ernest nucleus cracker extra delicate cross-action serrated paddle shaped jaws for cracking the nucleus through a 2.5 mm incision....
Epilation forceps straight ends size 3.5"....
Removal Forceps, very fine pointed tips, with textured jaws, ideal for grasping wet sutures....
Forceps, extra delicate, straight....
Medicine Products: